Government Grants
Business Grants
Home Owner Programs
Federal Programs
About Us
Registry of Medical Cannabis Use and Health Outcomes (UM1 - Clinical Trial Optional)
oAs of May 18, 2021, 36 US states and four territories allow for the medical use of cannabis products.
Current evidence from global database registries and other patient reported outcomes incorporate information from thousands of patients, but much of the evidence is based on anecdotal reports rather than possessing the robustness of randomized clinical trials, and these different types of sources are not always in agreement.
As many patients are already using cannabis products for medicinal applications, it is important to identify the evidence that exists and as it evolves, and to harmonize and coordinate this information to maximize the potential benefits to patients while minimizing harmful effects.
The goal of this cannabis registry is to gather information regarding medicinal cannabis products used as well as timing of, reasons for, and outcomes of use and impacts on other non-cannabis medication (e.g., opioids) use.
This coordinating center will also lead efforts in archiving and analyzing these data, as well as disseminating their findings.
Current evidence from global database registries and other patient reported outcomes incorporate information from thousands of patients, but much of the evidence is based on anecdotal reports rather than possessing the robustness of randomized clinical trials, and these different types of sources are not always in agreement.
As many patients are already using cannabis products for medicinal applications, it is important to identify the evidence that exists and as it evolves, and to harmonize and coordinate this information to maximize the potential benefits to patients while minimizing harmful effects.
The goal of this cannabis registry is to gather information regarding medicinal cannabis products used as well as timing of, reasons for, and outcomes of use and impacts on other non-cannabis medication (e.g., opioids) use.
This coordinating center will also lead efforts in archiving and analyzing these data, as well as disseminating their findings.
Agency: Department of Health and Human Services
Office: National Institutes of Health
Estimated Funding: $3,500,000
Office: National Institutes of Health
Estimated Funding: $3,500,000
Who's Eligible
Relevant Nonprofit Program Categories
Obtain Full Opportunity Text:
http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-23-011.html
Additional Information of Eligibility:
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U. S. Territory or Possession.
Full Opportunity Web Address:
http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-23-011.html
Contact:
Agency Email Description:
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.
Agency Email:
Date Posted:
2022-06-14
Application Due Date:
Archive Date:
2022-12-21
Social Entrepreneurship
Spotlight
When it Comes to Social Enterprises, Failure is the Best Platform for Innovation
In the world of social enterprises, failure is a cringe-worthy moment nobody wants to talk about. But, social entrepreneurs can benefit from their failures.
Learn How to Identify and Avoid Grant Scams
